Collectively, these results establish IGF2BP2 as a critical m6A regulator influencing BC subgroups, the tumor microenvironment, and clinical outcomes, highlighting its potential as a biomarker for therapeutic stratification in bladder cancer. Here, IGF2BP2 is linked to urinary bladder cancer.